


Weekly Case Trend Summary

Nov. 8, 2021 – Dec. 12, 2021

Total New Cases by Week



*Data for all cases reported
November 8 – December 12*

Total Cases: 1,118

81.0% were symptomatic

5.0% were asymptomatic


14.0% did not report symptom status

Hospitalizations: 56 inpatients

Deaths: 16 deaths

February –December 3rd, percentage of
breakthrough* cases: **1.47%**

Age Distribution by Week



Case Data by Vaccination Status

From Nov. 8 – Dec. 12, the majority of cases were **not vaccinated** at the time of this report.

58.8%
NOT VACCINATED

Among unvaccinated cases:

74.1% were symptomatic

3.7% were asymptomatic

22.2% did not report symptom status

Fully vaccinated individuals meet the following criteria:
(1) 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines,
OR
(2) 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen vaccine.

Not vaccinated/unvaccinated* includes those that do not meet the criteria of a fully vaccinated individual (outlined above).

Breakthrough cases are formally defined as the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person who is ≥ 14 days after completion all recommended doses of a U.S. Food and Drug Administration (FDA)-authorized COVID-19 vaccine.

Weekly Case Trend Summary


Nov. 8, 2021 – Dec. 12, 2021

To align with the Michigan Department of Health and Human Services (MDHHS) breakthrough case data, this page includes data for cases with a confirmatory COVID-19 test only.

Fully Vaccinated

Unvaccinated

Cases



Deaths



Hospitalizations



Fully vaccinated individuals meet the following criteria:
(1) 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines,
OR
(2) 2 weeks after a single-dose vaccine, such as Johnson & Johnson's Janssen vaccine.

Not vaccinated/unvaccinated includes those that do not meet the criteria of a fully vaccinated individual (outlined above).

Breakthrough cases are formally defined as the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person who is ≥14 days after completion all recommended doses of a U.S. Food and Drug Administration (FDA)-authorized COVID-19 vaccine.